The Dunedin-based company Pacific Edge has secured Medicare coverage for its bladder cancer detection technology in the United States. The decision follows a legal battle to confirm coverage for its Cxbladder Triage and Triage Plus tests.
The technology, developed by Pacific Edge, uses urine samples to detect early signs of bladder cancer. The Medicare approval allows patients in the US to access the tests without full out-of-pocket costs. The approval was confirmed by the Centers for Medicare & Medicaid Services.
Pacific Edge has been working to expand its presence in the US healthcare market. The company previously faced challenges in securing coverage for its technology. The recent approval marks a significant milestone in its efforts to make the tests more accessible. The technology has already been used in New Zealand and is now set to reach a larger patient base in the US.
